Analytical Data
-
基因名
LILRA6/CD85b/ILT8
-
简介
LILRA6/CD85b/ILT-8 protein serves as a receptor for class I MHC antigens and plays a crucial role in immune recognition and regulation. Its interaction with class I MHC molecules has been shown to be involved in monitoring and potentially modulating immune responses. LILRA6/CD85b/ILT-8 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LILRA6/CD85b/ILT-8 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
别名
7M1; CD85b; ILT8; LILRA6; Pira3
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A2K5VN04
-
表达区间
G41-H474
-
蛋白长度
Extracellular Domain
-
分子量
68-75 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRA6, also known as CD85b or ILT8, is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which plays a critical role in the immune system regulation. As an inhibitory receptor expressed on various immune cells, including monocytes and dendritic cells, LILRA6 is involved in modulating immune responses by recognizing major histocompatibility complex (MHC) class I molecules and other ligands. Recent research has highlighted its potential role in influencing tolerance and promoting immune evasion in certain diseases, including cancer and autoimmune disorders. The recombinant protein form of LILRA6 has been developed to facilitate in-depth studies into its structural characteristics and function, enabling researchers to explore its binding interactions and signaling pathways. Understanding the mechanisms by which LILRA6 operates could lead to novel therapeutic approaches to manipulate immune responses, enhance vaccine efficacy, or develop immunotherapies for challenging conditions like tumor immunology. Thus, the investigation of LILRA6/CD85b/ILT8 is of paramount importance for both fundamental immunology and clinical applications in improving health outcomes.
